Australia: A Strategic Gateway for Early Clinical Development
Authors:
Emelyn Davies, Director of Project Management, Oncology
Virgilio Garica Lerma, Executive Director, Global Regulatory Strategist
Megan Collett, Executive Director, APAC Operations
Geraldine Moune, Vice President, Regulatory Affairs and Site Contracts
Andrew Kuhlman, Clinical Research Specialist, Clinical Research Methodology
Source: Worldwide Clinical Trials
Abstract
Australia is a leading destination for clinical trials due to its active research ecosystem, streamlined regulatory pathways, and government support.1,2 Between 2006 and 2020, more than 18,000 trials with Australian sites were registered, reflecting high per-capita trial activity.1 Start-up timelines are often faster, with first patient in achievable in about three months for some early phase studies compared to six to nine months in the U.S. or E.U.3 Costs are also estimated to be ~28% lower than in the U.S. before incentives and up to 60% lower after Australia’s research and development (R&D) tax rebate.4 Additionally, the Therapeutic Goods Administration (TGA) framework allows many early-phase studies to proceed without a U.S. FDA Investigational New Drug (IND) application while maintaining rigorous oversight.3,5 Data generated in Australia may support FDA and EMA submissions, although region-specific requirements still apply.6
Operational challenges such as geographic distance, time zone differences, local sponsor requirements, and
import/export regulations do exist.6-8 Australia’s smaller population may also limit feasibility for very large Phase III programs. However, refundable R&D tax incentives covering approximately 38 – 43% of eligible expenditures can significantly extend development capital.9 Australian trials are conducted under the International Council for Harmonization’s Good Clinical Practice (ICH-GCP) standards, with regulatory credibility and intellectual property (IP) protections comparable to the U.S. and Europe.6 Collectively, Australia provides an attractive platform for accelerating early-stage clinical development while maintaining global regulatory acceptance.
Worldwide Homepage: https://www.worldwide.com/
Gateway Whitepaper: https://www.worldwide.com/
Download '.pdf' Format of the whitepaper.
